Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 22, Issue 15, Pages 2216-2237Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612822666160216150338
Keywords
Diabetes mellitus; periodontitis; inflammation; lipid mediators; pro-resolution therapeutics
Categories
Funding
- National Institute of Dental and Craniofacial Research through USPHS grants [K99DE024575, DE25030]
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE025020, K99DE024575, R00DE024575] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The increasing incidence of diabetes mellitus (DM) and chronic periodontitis (CP) worldwide imposes a rethinking of individualized therapy for patients with both conditions. Central to bidirectional links between DM and CP is deregulated systemic inflammation and dysfunctional immune responses to altered-self and non-self. Control of blood glucose levels and metabolic imbalances associated with hyperglycemia in DM, and disruption of pathogenic subgingival biofilms in CP are currently the main therapeutic approaches for these conditions. Mounting evidence suggests the need to integrate immune modulatory therapeutics in treatment regimens that address the unresolved inflammation associated with DM and CP. The current review discusses the pathogenesis of DM and CP with emphasis on deregulated inflammation, current therapeutic approaches and the novel pro-resolution lipid mediators derived from Omega-3 polyunsaturated fatty acids.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available